Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Exelixis Inc
(NQ:
EXEL
)
29.06
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
75
Open
29.06
Bid (Size)
28.95 (1)
Ask (Size)
29.40 (1)
Prev. Close
29.06
Today's Range
29.06 - 29.06
52wk Range
18.64 - 29.75
Shares Outstanding
315,048,788
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
Today 7:30 EDT
In a market where value is scarce, EXELIXIS INC (NASDAQ:EXEL) offers a refreshing opportunity with its solid fundamentals.
Via
Chartmill
Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
October 15, 2024
From
Exelixis, Inc.
Via
Business Wire
Performance
YTD
+21.44%
+21.44%
1 Month
+5.29%
+5.29%
3 Month
+28.81%
+28.81%
6 Month
+29.21%
+29.21%
1 Year
+36.11%
+36.11%
More News
Read More
Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories
October 15, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma
October 14, 2024
From
Exelixis, Inc.
Via
Business Wire
Blue Skies, New Highs Remain Disciplined And Do Not Chase Extended Ideas
October 13, 2024
Via
Talk Markets
Key Takeaways From Exelixis Analyst Ratings
October 04, 2024
Via
Benzinga
NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals.
September 27, 2024
Via
Chartmill
2 Growth Stocks to Buy With Less Than $100
September 26, 2024
Via
The Motley Fool
A Closer Look at 5 Analyst Recommendations For Exelixis
September 18, 2024
Via
Benzinga
Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
September 16, 2024
From
Exelixis, Inc.
Via
Business Wire
NASDAQ:EXEL, an undervalued stock with good fundamentals.
August 15, 2024
Via
Chartmill
Expert Outlook: Exelixis Through The Eyes Of 5 Analysts
August 08, 2024
Via
Benzinga
Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024
September 15, 2024
From
Exelixis, Inc.
Via
Business Wire
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
September 06, 2024
Via
Chartmill
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
August 28, 2024
From
Exelixis, Inc.
Via
Business Wire
3 Stocks to Buy for a Soft Landing, If There Is One
August 15, 2024
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
August 09, 2024
Via
Investor's Business Daily
Analyst Sees Exelixis At Inflection Point Despite Mixed Trial Results
August 07, 2024
Via
Benzinga
Exposures
Product Safety
Exelixis (EXEL) Q2 2024 Earnings Call Transcript
August 07, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
EXEL Stock Earnings: Exelixis Beats EPS, Beats Revenue for Q2 2024
August 06, 2024
Via
InvestorPlace
US Stocks Set To Extend Gains Despite Mixed Earnings, VIX Dips Back Toward Pre-Sell-Off Levels: Analyst Says Pullback Is A 'Growth Scare' And Not 'Calamity'
August 07, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 06, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors
August 06, 2024
From
Exelixis, Inc.
Via
Business Wire
Wall Street Rebounds After Selloff, VIX Falls, Dollar Surges Against Yen: What's Driving Markets Tuesday?
August 06, 2024
Via
Benzinga
Topics
Economy
Stocks
Exposures
Economy
US Equities
US Stocks Set To Open Higher After Monday's Crash, VIX Plummets: Analyst Says Would Have Worried If Market Surged Higher Without Correction
August 06, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.